Home › Research › Tau biomarkers
Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
Lane RM, Darreh-Shori T, Junge C, Li D, Yang Q, Edwards AL, Graham DL, Moore K et al.. BMC neurology, 2024-01-03
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background We wished to examine the impact of the K-variant of butyrylcholinesterase ( BCHE-K ) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers. Methods In 45 patients, aged 50-74 years, with cerebrospinal fluid (CSF) biomarker confirmed mild AD, recruited into a clinical trial ( NCT03186989 ), baseline demographics, disease characteristics, and biomarkers were evaluated by BCHE-K and APOE4 allelic status. Results In APOE4 carriers (N = 33), mean age-at-diagnosis of AD in BCHE-K carriers (n = 11) was 6.4 years earlier than in BCHE-K noncarriers (n = 22, P < .001, ANOVA). In APOE4 noncarriers (N = 12) there was no similar influence of BCHE-K . In APOE4 carriers with versus those without BCHE-K , mean age-at-baseline was over 6 years earlier and accompanied by slightly higher amyloid and tau accumulations. A predominant amyloid, limited tau pathophysiology, and limbic-amnestic phenotype was exemplified by APOE4 homozygotes with BCHE-K . Multiple regression analyses demonstrated association of amyloid accumulation with APOE4 carrier status ( P < .029), larger total brain ventricle volume ( P < .021), less synaptic injury (Ng, P < .001), and less tau (p-tau 181 , P < .005). In contrast, tau pathophysiology was associated with more neuroaxonal damage (NfL, P = .002), more synaptic injury (Ng, P < .001), and higher levels of glial activation (YKL-40, P = .01). Conclusion Findings: concern the genetic architecture of prognosis in early AD, that is fundamental for patients and the design of clinical trials, and that is less well established than the genetics of susceptibility. In mild AD patients aged less than 75 years, the mean age-at-diagnosis of AD in APOE4 carriers was reduced by over 6 years in BCHE-K carriers versus noncarriers. Functional activation of glia may explain much of the effects of APOE4 and BCHE-K on the phenotype of early AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lane, R. M., Darreh-Shori, T., Junge, C., Li, D., Yang, Q., Edwards, A. L., et al. (2024). Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers. BMC neurology. https://doi.org/10.1101/2024.01.02.24300718
Vancouver
Lane RM, Darreh-Shori T, Junge C, Li D, Yang Q, Edwards AL, et al. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers. BMC neurology. 2024. doi:10.1101/2024.01.02.24300718.
BibTeX
@article{lane2024-2fcd5460,
author = {Lane, R. M. and Darreh-Shori, T. and Junge, C. and Li, D. and Yang, Q. and Edwards, A. L. and Graham, D. L. and Moore, K. and others},
title = {{Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers}},
journal = {BMC neurology},
year = {2024},
doi = {10.1101/2024.01.02.24300718},
url = {https://doi.org/10.1101/2024.01.02.24300718}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results In APOE4 carriers (N = 33), mean age-at-diagnosis of AD in BCHE-K carriers (n = 11) was 6.4 years earlier than in BCHE-K noncarriers (n = 22, P < .001, ANOVA).
- In APOE4 carriers with versus those without BCHE-K , mean age-at-baseline was over 6 years earlier and accompanied by slightly higher amyloid and tau accumulations.
- Multiple regression analyses demonstrated association of amyloid accumulation with APOE4 carrier status ( P < .029), larger total brain ventricle volume ( P < .021), less synaptic injury (Ng, P < .001), and less tau (p-tau 181 , P < .005).
- In contrast, tau pathophysiology was associated with more neuroaxonal damage (NfL, P = .002), more synaptic injury (Ng, P < .001), and higher levels of glial activation (YKL-40, P = .01).
- In mild AD patients aged less than 75 years, the mean age-at-diagnosis of AD in APOE4 carriers was reduced by over 6 years in BCHE-K carriers versus noncarriers.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants33
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 28 of the 58 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 33 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38594621) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 28 of the 58 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.